242 related articles for article (PubMed ID: 21732759)
1. Somatostatin receptors in non-neuroendocrine malignancies: the potential role of somatostatin analogs in solid tumors.
Hasskarl J; Kaufmann M; Schmid HA
Future Oncol; 2011 Jul; 7(7):895-913. PubMed ID: 21732759
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical and clinical experiences with novel somatostatin ligands: advantages, disadvantages and new prospects.
Hofland LJ; van der Hoek J; Feelders R; van der Lely AJ; de Herder W; Lamberts SW
J Endocrinol Invest; 2005; 28(11 Suppl International):36-42. PubMed ID: 16625843
[TBL] [Abstract][Full Text] [Related]
3. Role of somatostatin analogs in the clinical management of non-neuroendocrine solid tumors.
Kvols LK; Woltering EA
Anticancer Drugs; 2006 Jul; 17(6):601-8. PubMed ID: 16917205
[TBL] [Abstract][Full Text] [Related]
4. Pasireotide in the treatment of neuroendocrine tumors: a review of the literature.
Vitale G; Dicitore A; Sciammarella C; Di Molfetta S; Rubino M; Faggiano A; Colao A
Endocr Relat Cancer; 2018 Jun; 25(6):R351-R364. PubMed ID: 29643113
[TBL] [Abstract][Full Text] [Related]
5. Effects of somatostatin analogs on glucose homeostasis in rats.
Schmid HA; Brueggen J
J Endocrinol; 2012 Jan; 212(1):49-60. PubMed ID: 21987782
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin analogs and radiopeptides in cancer therapy.
Froidevaux S; Eberle AN
Biopolymers; 2002; 66(3):161-83. PubMed ID: 12385036
[TBL] [Abstract][Full Text] [Related]
7. SOM230 inhibits insulin-like growth factor-I action in mammary gland development by pituitary independent mechanism: mediated through somatostatin subtype receptor 3?
Ruan W; Fahlbusch F; Clemmons DR; Monaco ME; Walden PD; Silva AP; Schmid HA; Kleinberg DL
Mol Endocrinol; 2006 Feb; 20(2):426-36. PubMed ID: 16223973
[TBL] [Abstract][Full Text] [Related]
8. Potential indications for somatostatin analogues: immune system and limphoproliferative disorders.
Ferone D; Resmini E; Boschetti M; Arvigo M; Albanese V; Ceresola E; Pivonello R; Albertelli M; Bianchi F; Giusti M; Minuto F
J Endocrinol Invest; 2005; 28(11 Suppl International):111-7. PubMed ID: 16625859
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
10. Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in vitro.
Lesche S; Lehmann D; Nagel F; Schmid HA; Schulz S
J Clin Endocrinol Metab; 2009 Feb; 94(2):654-61. PubMed ID: 19001514
[TBL] [Abstract][Full Text] [Related]
11. Pasireotide, a multi-somatostatin receptor ligand with potential efficacy for treatment of pituitary and neuroendocrine tumors.
Feelders RA; de Herder WW; Neggers SJ; van der Lely AJ; Hofland LJ
Drugs Today (Barc); 2013 Feb; 49(2):89-103. PubMed ID: 23462624
[TBL] [Abstract][Full Text] [Related]
12. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
13. Short- and long-term effects of octreotide and SOM230 on GH, IGF-I, ACTH, corticosterone and ghrelin in rats.
Schmid HA; Silva AP
J Endocrinol Invest; 2005; 28(11 Suppl International):28-35. PubMed ID: 16625842
[TBL] [Abstract][Full Text] [Related]
14. Investigational drugs targeting somatostatin receptors for treatment of acromegaly and neuroendocrine tumors.
Giustina A; Mazziotti G; Maffezzoni F; Amoroso V; Berruti A
Expert Opin Investig Drugs; 2014 Dec; 23(12):1619-35. PubMed ID: 25060168
[TBL] [Abstract][Full Text] [Related]
15. Physiology of somatostatin receptors.
Guillermet-Guibert J; Lahlou H; Cordelier P; Bousquet C; Pyronnet S; Susini C
J Endocrinol Invest; 2005; 28(11 Suppl International):5-9. PubMed ID: 16625838
[TBL] [Abstract][Full Text] [Related]
16. Activities of bone morphogenetic proteins in prolactin regulation by somatostatin analogs in rat pituitary GH3 cells.
Tsukamoto N; Otsuka F; Miyoshi T; Inagaki K; Nakamura E; Suzuki J; Ogura T; Iwasaki Y; Makino H
Mol Cell Endocrinol; 2011 Jan; 332(1-2):163-9. PubMed ID: 20970474
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin analogs in the treatment of neuroendocrine gastroenteropancreatic and intrathoracic tumors.
Janson ET
J Endocrinol Invest; 2005; 28(11 Suppl International):137-40. PubMed ID: 16625863
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo detection of functional somatostatin receptors in canine insulinomas.
Robben JH; Visser-Wisselaar HA; Rutteman GR; van Rijk PP; van Dongen AJ; Voorhout G; van den Ingh TS; Hofland LJ; Lamberts SW
J Nucl Med; 1997 Jul; 38(7):1036-42. PubMed ID: 9225787
[TBL] [Abstract][Full Text] [Related]
19. Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion.
Zatelli MC; Piccin D; Vignali C; Tagliati F; Ambrosio MR; Bondanelli M; Cimino V; Bianchi A; Schmid HA; Scanarini M; Pontecorvi A; De Marinis L; Maira G; degli Uberti EC
Endocr Relat Cancer; 2007 Mar; 14(1):91-102. PubMed ID: 17395978
[TBL] [Abstract][Full Text] [Related]
20. Somatostatin receptors: from signaling to clinical practice.
Theodoropoulou M; Stalla GK
Front Neuroendocrinol; 2013 Aug; 34(3):228-52. PubMed ID: 23872332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
